GRCL News and Press, Gracell Biotechnologies Inc. From 11/13/23

Dosed first patient in Phase 1b/2 clinical trial in the US evaluating FasTCAR-T GC012F for the treatment of relapsed/refractory multiple myeloma (RRMM) Expect to commence Phase 1/2 clinical trial in China evaluating GC012F for the treatment of RRMM in the fourth quarter 2023 Prese...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Gracell Biotechnologies Inc. (GRCL) is expected to report $-0.26 for Q3 2023

Third annual BioTech Breakthrough Award recognizes excellence in life science and biotechnology solutions, services and companies GC012F, a FasTCAR-enabled autologous CAR-T cell therapy, is currently being evaluated in clinical studies in multiple hematological cancers as well as au...

Oral presentation of the updated results from ongoing Phase 1 investigator-initiated study of GC012F in frontline setting for transplant-eligible, high-risk newly diagnosed multiple myeloma GC012F is a FasTCAR-enabled B-cell maturation antigen (BCMA) and CD19 dual-targeting autologous c...

Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment (TME) and maintained long-term proliferation and cytotoxicity both in vitro and in vivo ...

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of...

2023-10-19 15:49:11 ET More on Gracell Biotechnologies Gracell Biotechnologies: A CAR-T Company Flying Under Your Radar Gracell Biotechnologies Inc. (GRCL) Q2 2023 Earnings Call Transcript Gracell Biotechnologies jumps 14% on $150M private placement Seeking A...

2023-10-18 17:39:01 ET Gainers: Netflix ( NFLX ) +12% . Melco Resorts & Entertainment  ( MLCO ) +5% . ADTRAN Holdings ( ADTN ) +4% . Acumen Pharmaceuticals ( ABOS ) +4% . Gracell Biotechnologies  ( GRCL ) +4% . ...

2023-10-01 03:30:00 ET Summary Adlai Nortye completes a $97.5 million IPO on NASDAQ, with its lead drug in a Phase III clinical trial for head and neck squamous cell carcinoma. Nanjing Triastek raises $20 million in a Pre-C financing round to support the development of its 3D prin...